Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.81 +1.1%	$20.66	$13.40 ▼ $25.23	$3.65B	0.64	2.25 million shs	577,975 shs
ORIC Oric Pharmaceuticals	$11.22 +2.9%	$8.01	$3.90 ▼ $14.67	$959.62M	1.54	788,184 shs	355,530 shs
RNA Avidity Biosciences	$31.45 +0.6%	$30.51	$21.51 ▼ $56.00	$3.78B	0.91	1.38 million shs	1.83 million shs
SWTX SpringWorks Therapeutics	$46.99	$46.63	$28.21 ▼ $62.00	$3.54B	0.68	2.59 million shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+2.62%	+1.55%	-3.27%	+52.87%	+25.92%
ORIC Oric Pharmaceuticals	+4.51%	+2.35%	+10.55%	+152.90%	+16.70%
RNA Avidity Biosciences	+6.91%	+6.51%	-4.26%	+29.70%	-22.54%
SWTX SpringWorks Therapeutics	0.00%	0.00%	+0.51%	+36.48%	+22.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6833 of 5 stars	4.4	3.0	0.0	3.3	4.2	2.5
ORIC Oric Pharmaceuticals	4.6214 of 5 stars	4.5	1.0	4.4	2.4	3.3	0.6
RNA Avidity Biosciences	2.4751 of 5 stars	4.5	0.0	0.0	3.3	0.8	0.0
SWTX SpringWorks Therapeutics	1.6508 of 5 stars	3.1	2.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	27.83% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	65.58% Upside
RNA Avidity Biosciences	3.06	Buy	$65.35	107.79% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside

Current Analyst Ratings Breakdown

Latest ORIC, SWTX, RNA, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.81	$0.73 per share	29.82	$4.40 per share	4.96
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
RNA Avidity Biosciences	$10.90M	347.76	N/A	N/A	$11.94 per share	2.63
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.92	28.69	4.53	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest ORIC, SWTX, RNA, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	SWTX SpringWorks Therapeutics	-$0.81	N/A	N/A	N/A	$73.39 million	N/A
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
RNA Avidity Biosciences	N/A	16.91	16.91
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ORIC Oric Pharmaceuticals	95.05%
RNA Avidity Biosciences	N/A
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ORIC Oric Pharmaceuticals	6.82%
RNA Avidity Biosciences	3.83%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

ORIC, SWTX, RNA, and ACAD Headlines

Recent News About These Companies

Principal Financial Group Inc. Trims Stake in SpringWorks Therapeutics (NASDAQ:SWTX)

July 7 at 4:48 AM | marketbeat.com

37,543 Shares in SpringWorks Therapeutics (NASDAQ:SWTX) Bought by CIBRA Capital Ltd

July 2, 2025 | marketbeat.com

SpringWorks Therapeutics Completes Merger and Delisting

July 1, 2025 | tipranks.com

SpringWorks Therapeutics Inc (SWTX) - Investing.com

June 28, 2025 | investing.com

AMI Asset Management Corp Purchases 10,849 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 26, 2025 | marketbeat.com

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24, 2025 | msn.com

SG Americas Securities LLC Buys 9,409 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 21, 2025 | marketbeat.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.comQ

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

GAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 19, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts

June 17, 2025 | marketbeat.com

Biotech Stocks To Consider - June 16th

June 16, 2025 | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - Here's Why

June 16, 2025 | marketbeat.com

FNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

Assenagon Asset Management S.A. Takes $3.52 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 26, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off

ORIC, SWTX, RNA, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.81 +0.24 (+1.09%)

As of 02:25 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Oric Pharmaceuticals NASDAQ:ORIC

$11.22 +0.32 (+2.90%)

As of 02:25 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Avidity Biosciences NASDAQ:RNA

$31.45 +0.18 (+0.58%)

As of 02:25 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)

As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time